Cover Image
市場調查報告書

神經調節設備市場 2017年∼2027年:腦深部刺激療法,脊髓,迷走神經,薦骨神經及胃電刺激用途的收益預測

Neuromodulation Devices Report 2017-2027: Revenue Forecasts for Deep Brain Stimulation, Spinal Cord, Vagus Nerve, Sacral Nerve and Gastric Electrical Applications

出版商 Visiongain Ltd 商品編碼 585547
出版日期 內容資訊 英文 195 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
神經調節設備市場 2017年∼2027年:腦深部刺激療法,脊髓,迷走神經,薦骨神經及胃電刺激用途的收益預測 Neuromodulation Devices Report 2017-2027: Revenue Forecasts for Deep Brain Stimulation, Spinal Cord, Vagus Nerve, Sacral Nerve and Gastric Electrical Applications
出版日期: 2017年11月01日 內容資訊: 英文 195 Pages
簡介

本報告提供全球神經調節設備的市場調查,市場定義和概要,產品、技術的分類與各種用途、刺激處趨勢與市場規模的變化與預測,各地區、主要國家的詳細分析,主要企業簡介等彙整。

第1章 報告概要

第2章 簡介:神經調節

  • 神經調節
  • 神經調節的各種技術
    • 電刺激
    • 藥物療法
  • 神經調節的各種用途
    • 疼痛
    • 憂鬱
    • 便、尿失禁
    • 聽覺障礙
    • 心血管疾病:心律不整、心絞痛
    • 神經退化性疾病:帕金森氏症

第3章 全球市場分析、預測

  • 市場成果
  • 市場預測
  • 產業趨勢

第4章 脊髓刺激部門分析、預測

  • 市場概要
  • 市場預測
  • 暢銷產品、開發中的產品
  • 各種用途
  • 市場趨勢、預測

第5章 腦深部刺激部門分析、預測

  • 市場概要
  • 市場預測
  • 暢銷產品、開發中的產品
  • 各種用途
  • 市場趨勢、預測

第6章 胃電刺激部門分析、預測

  • 市場概要
  • 市場預測
  • 暢銷產品、開發中的產品
  • 各種用途
  • 市場趨勢、預測

第7章 迷走神經刺激部門分析、預測

  • 市場概要
  • 市場預測
  • 暢銷產品、開發中的產品
  • 各種用途
  • 市場趨勢、預測

第8章 薦椎神經刺激部門分析、預測

  • 市場概要
  • 市場預測
  • 暢銷產品、開發中的產品
  • 各種用途
  • 市場趨勢、預測

第9章 其他神經調節技術部門分析、預測

  • 技術概要
    • 三叉神經刺激
    • 人工電子耳
    • 經顱磁刺激 (TMS)
    • 經顱直流刺激(tDCS)
    • 超音波神經調節
  • 市場預測

第10章 主要先進國家市場的趨勢、預測

  • 美國
  • 日本
  • 德國
  • 法國
  • 義大利
  • 英國
  • 西班牙

第11章 主要新興國家市場的趨勢、預測

  • 巴西
  • 中國
  • 印度
  • 俄羅斯

第12章 主要製造商

  • Medtronic
  • Boston Scientific
  • St. Jude Medical(SJM)
  • Cyberonics
  • 其他

第13章 定性分析

  • SWOT分析
  • STEP分析
  • 致力於臨床試驗的企業

第14章 總論

目錄
Product Code: PHA0255

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 195-page report you will receive 33 tables and 61 figures all unavailable elsewhere.

The 195-page report provides clear detailed insight into the neuromodulation devices market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

The revenue of the neuromodulation devices market in 2016 was estimated at $3.77bn and is expected to grow at a CAGR of 11.6% in the first half of the forecast period. The spinal cord stimulation segment accounted for the largest share of the market in 2016, this segment generated $1.89bn.

Read on to discover how this definitive report can transform your own research and save you time.

The new market assessment benefits research, analysis and planning in seven main ways:

  • The Neuromodulation Devices Market To 2027 - Discover That Industry's Overall Sales Potential
  • 5 Submarket Revenues To 2027 - Investigate Categories at World Level, Finding the Most Promising Therapies
  • 12 National Markets in The Americas, Europe And Asia Covered, With Forecasts To 2027
  • Activities of Established, Rising and Emerging Companies - Hear About Firms' Products, Capabilities, Advances, Collaborations and Outlooks, Mergers and Acquisitions, Research and Development
  • Investigate Progress in The Industry, Exploring Technological, Clinical and Commercial Opportunities
  • Analysis of What Stimulates and Restrains That Industry and Market - Assess Challenges, Strengths, Competition and Opportunities, Helping You Succeed.
  • Discover Neuromodulation Devices Currently in Pipeline and Which Companies Are Active in Clinical Trials for Market Approvals

There you explore business intelligence with research, opinions and predictions found only in that work.

Trying our investigation now lets you discover trends, opportunities and prospects for neuromodulation devices our report shows you data, trends, opportunities and multilevel sales forecasts.

Report highlights

195 pages, 33 tables and 61 figures

The Neuromodulation Devices Market from 2017 to 2027

This report also breaks down the revenue forecast for the 6 main submarkets:

  • Spinal Cord Stimulation
  • Sacral Nerve Stimulation
  • Vagus Nerve Stimulation
  • Deep Brain Stimulation
  • Gastric Electric Stimulation
  • Others - trigeminal nerve stimulation, cochlear implants, transcranial magnetic stimulation, transcranial direct current stimulation and ultrasonic neuromodulation techniques.

Analysis of key players in Neuromodulation Devices Market:

  • Medtronic
  • Boston Scientific
  • St Jude Medical (Subsidiary of Abbott Diagnostics)
  • Cyberonics (Subsidiary of LivaNova)
  • Stryker Corporation
  • Nevro Corp.
  • SetPoint Medical
  • Functional Neuromodulation
  • Neurotherapies Reset
  • Wringless Implantable Stretchable Electronics (WISE)

Regional the Neuromodulation Devices Market forecasts from 2017-2027

  • US forecast 2017-2027,
  • China forecast 2017-2027
  • Japan forecast 2017-2027
  • India forecast 2017-2027
  • Germany forecast 2017-2027
  • UK forecast 2017-2027
  • France forecast 2017-2027
  • Italy forecast 2017-2027
  • Spain forecast 2017-2027
  • Brazil forecast 2017-2027
  • Russia forecast 2017-2027

Key questions answered

  • What is neuromodulation? What is the importance of neuromodulation devices, and why are they effective?
  • What is the current size of the overall world neuromodulation devices market? How much will this market be worth from 2017 to 2027?
  • What are the main drivers and restraints that will shape the overall neuromodulation devices market over the next ten years?
  • What are the main segments within the overall neuromodulation devices market? How much will each of these segments be worth during the period 2017-2027? How will the composition of the market change during that time, and why?
  • What factors will affect segments of the market over the next ten years?
  • What are the largest national markets for neuromodulation devices? What is their current status and how will they develop over the next ten years? What are their sales forecasts for 2017-2027?
  • How will political and regulatory factors influence regional markets?
  • How will the market shares of the national markets change by 2027 and which geographical region will lead the market in 2027?
  • Who are the leading companies for neuromodulation devices and what do they do?
  • What are the predictions for existing players and the prospects for new market entrants?
  • What are the main trends that will affect the neuromodulation devices market between 2017 and 2027?
  • What are the main strengths, weaknesses, opportunities and threats for the market?
  • What are the social, technological, economic and political influences that will shape that market over the next ten years?
  • How will the global neuromodulation devices market evolve over the forecasted period of 2017-2027, including its revenues?

Target audience

  • Leading Hepatitis C companies
  • Suppliers
  • Contractors
  • Technologists
  • R&D staff
  • Consultants
  • Analysts
  • CEO's
  • CIO's
  • COO's
  • Business development managers
  • Investors
  • Governments
  • Agencies
  • Industry organisations
  • Banks

With our study you see how that market can develop and perform, benefiting your reputation for insight and authority.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the World Market for Neuromodulation Devices
  • 1.2. Why You Should Read This Report
  • 1.3. How this Report Delivers
  • 1.4. Main Questions Answered by this Analysis
  • 1.5. Who is this Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions(FAQ)
  • 1.9. About Visiongain

2. Introduction to Neuromodulation

  • 2.1. Neuromodulation
  • 2.2. Techniques Used in Neuromodulation
    • 2.2.1. Electrical Stimulation Techniques
      • 2.2.1.1. Brain and Spinal Cord Therapies
      • 2.2.1.2. Cranial Nerve Stimulation
      • 2.2.1.3. Functional Electrical Stimulation
    • 2.2.2. Pharmacological Therapy
  • 2.3. Application of Neuromodulation
    • 2.3.1. Pain
    • 2.3.2. Depression
    • 2.3.3. Epilepsy
    • 2.3.4. Faecal and Urinary Incontinence
    • 2.3.5. Hearing Disorders-Profound Deafness
    • 2.3.6. Cardiovascular Diseases-Arrhythmia and Angina
    • 2.3.7. Neurodegenerative Diseases-Parkinson's Disease

3. The Global Neuromodulation Devices Market, 2017-2027

  • 3.1. Global Neuromodulation Devices Market: 2016
  • 3.2. Global Neuromodulation Devices Forecast: 2016-2027
  • 3.3. Neuromodulation Devices: Industry Trends, 2016-2027
    • 3.3.1. Industry Trends-Ageing Population
    • 3.3.2. Rising Prevalence of Chronic Diseases
    • 3.3.3. Industry Trends-Personalised Healthcare
    • 3.3.4. Industry Trends-National Regulations
    • 3.3.5. Political Uncertainty and Security Risk across the World
    • 3.3.6. Industry Trends-Economic Challenges
    • 3.3.7. Industry Trends-Mergers and Acquisitions

4. Spinal Cord Stimulation Submarket, 2017-2027

  • 4.1. Spinal Cord Stimulation(SCS) Market Overview, 2016
  • 4.2. SCS Market Forecast: 2016-2027
  • 4.3. Top Selling & Pipeline SCS Devices, 2017
  • 4.4. Applications of Spinal Cord Stimulation
  • 4.5. SCS Market Trends: 2017-2027

5. Deep Brain Stimulation Submarket, 2017-2027

  • 5.1. Deep Brain Stimulation(DBS) Market Overview, 2016
  • 5.2. DBS Market Forecast: 2016-2027
  • 5.3. Top Selling & Pipeline DBS Devices, 2017
  • 5.4. Applications of Deep Brain Stimulation
  • 5.5. DBS Market Trends: 2017-2027

6. Gastric Electrical Stimulation Submarket, 2017-2027

  • 6.1. Gastric Electrical Stimulation(GES) Market Overview, 2016
  • 6.2. GES Market Forecast: 2016-2027
  • 6.3. Top Selling GES Devices, 2017
  • 6.4. Applications of Gastric Electrical Stimulation
  • 6.5. GES Market Trends: 2017-2027

7. Vagus Nerve Stimulation Submarket, 2017-2027

  • 7.1. Vagus Nerve Stimulation(VNS) Market Overview, 2016
  • 7.2. VNS Market Forecast: 2016-2027
  • 7.3. Top Selling & Pipeline VNS Devices, 2017
  • 7.4. Applications of Vagus Nerve Stimulation
  • 7.5. VNS Market Trends: 2017-2027

8. Sacral Nerve Stimulation Submarket, 2017-2027

  • 8.1. Sacral Nerve Stimulation(SNS) Market Overview, 2016
  • 8.2. SNS Market Forecast: 2016-2027
  • 8.3. Top Selling & Pipeline SNS Devices, 2017
  • 8.4. Applications of Sacral Nerve Stimulation
  • 8.5. SNS Market Trends: 2017-2027

9. Other Neuromodulation Technologies Submarket, 2017-2027

  • 9.1. Other Neuromodulation Technologies Overview, 2016
    • 9.1.1. Trigeminal Nerve Stimulation
    • 9.1.2. Cochlear Implants
    • 9.1.3. Transcranial Magnetic Stimulation(TMS)
    • 9.1.4. Transcranial Direct Current Stimulation(tDCS)
    • 9.1.5. Ultrasonic Neuromodulation
  • 9.2. Other Neuromodulation Techniques Forecast: 2017-2027

10. Neuromodulation Devices in Leading National Developed Markets 2017-2027

  • 10.1. Neuromodulation Devices: Leading Developed Markets, 2016
  • 10.2. The US Neuromodulation Devices Market: 2017-2027
    • 10.2.1. The US Neuromodulation Devices Market: 2016
    • 10.2.2. The US Neuromodulation Devices Market Forecast: 2016-2027
  • 10.3. The Japanese Neuromodulation Devices Market: 2017-2027
    • 10.3.1. The Japanese Neuromodulation Devices Market: 2016
    • 10.3.2. The Japanese Neuromodulation Devices Market Forecast: 2016-2027
    • 10.3.3. The Effects of Regulations on the Japanese Market
  • 10.4. The German Neuromodulation Devices Market: 2017-2027
    • 10.4.1. The German Neuromodulation Devices Market: 2016
    • 10.4.2. The German Neuromodulation Devices Market Forecast: 2016-2027
  • 10.5. The French Neuromodulation Devices Market: 2017-2027
    • 10.5.1. The French Neuromodulation Devices Market: 2016
    • 10.5.2. The French Neuromodulation Devices Market Forecast: 2016-2027
    • 10.5.3. The French Neuromodulation Devices Market-the Economy and its Implications
  • 10.6. The Italian Neuromodulation Devices Market: 2017-2027
    • 10.6.1. The Italian Neuromodulation Devices Market: 2016
    • 10.6.2. The Italian Neuromodulation Devices Market Forecast: 2016-2027
    • 10.6.3. The Italian Neuromodulation Devices Market Outlook
  • 10.7. The UK Neuromodulation Devices Market: 2017-2027
    • 10.7.1. The UK Neuromodulation Devices Market: 2016
    • 10.7.2. The UK Neuromodulation Devices Market Forecast: 2016-2027
    • 10.7.3. The UK Neuromodulation Devices Market Forecast-Political Challenges
  • 10.8. The Spanish Neuromodulation Devices Market: 2017-2027
    • 10.8.1. The Spanish Neuromodulation Devices Market: 2016
    • 10.8.2. The Spanish Neuromodulation Devices Market Forecast: 2016-2027
    • 10.8.3. The Spanish Neuromodulation Devices Outlook

11. Neuromodulation Devices in Leading Emerging Markets 2017-2027

  • 11.1. Neuromodulation Devices: Leading Emerging Markets, 2016
  • 11.2. The Brazilian Neuromodulation Devices Market: 2017-2027
    • 11.2.1. The Brazilian Neuromodulation Devices Market: 2016
    • 11.2.2. The Brazilian Neuromodulation Device Market Forecast: 2016-2027
    • 11.2.3. The Brazilian Neuromodulation Devices Market: Economic and Political Challenges Affecting Prospects
  • 11.3. The Chinese Neuromodulation Devices Market: 2017-2027
    • 11.3.1. The Chinese Neuromodulation Devices Market: 2016
    • 11.3.2. The Chinese Neuromodulation Devices Market Forecast: 2016-2027
    • 11.3.3. The Chinese Neuromodulation Devices Market: Amendments to Regulations.
  • 11.4. The Indian Neuromodulation Devices Market: 2017-2027
    • 11.4.1. The Indian Neuromodulation Devices Market: 2016
    • 11.4.2. The Indian Neuromodulation Devices Market Forecast: 2016-2027
  • 11.5. The Russian Neuromodulation Devices Market: 2017-2027
    • 11.5.1. The Russian Neuromodulation Devices Market: 2016
    • 11.5.2. The Russian Neuromodulation Devices Market Forecast: 2016-2027

12. Neuromodulation Devices Market: Manufacturers

  • 12.1. Medtronic
    • 12.1.1. Sales and Recent Performance Analysis: 2016
    • 12.1.2. Medtronic International Operations
    • 12.1.3. Medtronic-Neuromodulation Performance
    • 12.1.4. Medtronic News
      • 12.1.4.1. Medtronic Mergers
      • 12.1.4.2. Expansion into DBS Market
      • 12.1.4.3. Medtronic Products
    • 12.1.5. Medtronic Market Outlook
  • 12.2. Boston Scientific
    • 12.2.1. Sales and Recent Performance Analysis: 2015
    • 12.2.2. Boston Scientific International Operations
    • 12.2.3. Boston Scientific-Neuromodulation Performance
    • 12.2.4. Boston Scientific News
      • 12.2.4.1. Boston Scientific Acquisitions
      • 12.2.4.2. Expansion into DBS Market
      • 12.2.4.3. Boston Scientific Products
    • 12.2.5. Boston Scientific Market Outlook
  • 12.3. St. Jude Medical(SJM)(now a Abbott company)
    • 12.3.1. Sales and Recent Performance Analysis: 2015
    • 12.3.2. SJM International Operations
    • 12.3.3. SJM-Neuromodulation Performance
    • 12.3.4. SJM News
      • 12.3.4.1. SJM Acquired by Abbott Medical
      • 12.3.4.2. SJM Acquisition
      • 12.3.4.3. SJM Products
    • 12.3.5. SJM-Market Outlook
  • 12.4. Cyberonics(now a LivaNova Company)
    • 12.4.1. Sales and Recent Performance Analysis: 2016
    • 12.4.2. Cyberonics(LivaNova Company) International Operations
    • 12.4.3. Cyberonics(now a LivaNova company)-Neuromodulation Performance
    • 12.4.4. Cyberonics News
      • 12.4.4.1. Cyberonics(LivaNova Company) Investments
      • 12.4.4.2. Cyberonics(LivaNova) Products
    • 12.4.5. Cyberonics(LivaNova) Market Outlook
  • 12.5. Other Companies
    • 12.5.1. Stryker Corporation
    • 12.5.2. Nevro Corp.
    • 12.5.3. SetPoint Medical
    • 12.5.4. Functional Neuromodulation
    • 12.5.5. Neurotherapies Reset
    • 12.5.6. Wiringless Implantable Stretchable Electronics(WISE)
    • 12.5.7. SceneRay
    • 12.5.8. Mindray

13. Qualitative Analysis of the Neuromodulation Devices Market, 2017

  • 13.1. SWOT Analysis of the Neuromodulation Devices Market
    • 13.1.1. Strengths of the Market
      • 13.1.1.1. An Ageing Population
      • 13.1.1.2. Alternative Form of Treatment
      • 13.1.1.3. Convenience
      • 13.1.1.4. Long-term Effectiveness
    • 13.1.2. Weaknesses
      • 13.1.2.1. Research and Development(R&D)
      • 13.1.2.2. Oligarchic Market
      • 13.1.2.3. Adverse Side-Effects of Implantation
      • 13.1.2.4. Shortage of Trained Professionals
    • 13.1.3. Opportunities in the Neuromodulation Devices Market
      • 13.1.3.1. The Advancement of Research
      • 13.1.3.2. A Shift Towards Personalisation
      • 13.1.3.3. Expanding the Target Applications of the Devices
      • 13.1.3.4. Outsource Manufacturing of Devices
    • 13.1.4. Threats Facing the Neuromodulation Devices Market
      • 13.1.4.1. The Challenge of Regulation
  • 13.2. STEP Analysis of the Neuromodulation Devices Market
    • 13.2.1. Social Factors: The Role of Neuroethics
    • 13.2.2. Technological Developments: Drive towards Non-Invasive Methods
    • 13.2.3. Economic Restraints: High Production Costs
    • 13.2.4. Economic Potential: Emerging Markets Create Demand
    • 13.2.5. Political Issues: Strong Government Influence
  • 13.3. Snapshot of Companies in Active Clinical Trials
    • 13.3.1. Neuromodulation Pipeline Products -2016-2017

14. Conclusions

  • 14.1. The United States Retains its Position as Market Leader
  • 14.2. Growing Incidences of Neurological Diseases
  • 14.3. Ageing Population Drives Growth
  • 14.4. China and India will Lead the Emerging Markets
  • 14.5. The Future of the Market-Deep Brain Stimulation and Vagus Nerve Stimulation
  • 14.6. Concluding Remarks

Associated Visiongain Reports

  • Visiongain Report Sales Order Form
  • About Visiongain
  • Appendix B
  • Visiongain Report Evaluation Form

Table of Tables

  • Table 1.1: Selected National Neuromodulation Devices Markets: Revenues($mn) and Market Shares(%) by Leading Country, 2016, 2022 and 2027(sample table)
  • Table 3.1: World Neuromodulation Devices Submarkets: Revenue($mn), AGR(%), CAGRs(%), Market Share(%), 2016-2027
  • Table 3.2: Global Neuromodulation Devices Markets: Revenue($mn), AGR(%), CAGR(%), 2016-2027
  • Table 4.1: SCS Devices Forecast($mn), AGR(%), Market Share and CAGR(%), 2016-2027
  • Table 4.2: Leading & Pipeline SCS Devices, 2017
  • Table 5.1: The DBS Devices Forecast($mn), AGR(%), Market Share and CAGR(%), 2016-2027
  • Table 5.2: Leading & Pipeline DBS Devices, 2017
  • Table 6.1: The GES Devices Forecast($mn), AGR(%), Market Share and CAGR(%), 2016-2027
  • Table 6.2: Leading GES Devices, 2017
  • Table 7.1: The VNS Devices Forecast($mn), AGR,(%), Market Share and CAGR(%), 2016-2027
  • Table 7.2: Leading VNS & Pipeline Devices, 2017
  • Table 8.1: The SNS Devices Forecast($mn), AGR(%), Market Share and CAGR(%), 2016-2027
  • Table 8.2: Leading & Pipeline SNS Devices, 2017
  • Table 9.1: Leading & Pipeline Other Neuromodulation Devices, 2017
  • Table 9.2: Other Neuromodulation Devices Market: Revenue Forecast($mn), AGR(%), Market Share and CAGR(%), 2016-2027
  • Table 10.1: Regional Neuromodulation Devices Markets: Revenue($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 10.2: The US Neuromodulation Devices: Revenue Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 10.3: The Japanese Neuromodulation Devices Revenue Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 10.4: The German Neuromodulation Devices Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 10.5: The French Neuromodulation Devices Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 10.6: The Italian Neuromodulation Devices Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 10.7: The UK Neuromodulation Devices Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 10.8: The Spanish Neuromodulation Devices Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 11.1: Neuromodulation Devices Emerging Markets: Revenue($bn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 11.2: The Brazilian Neuromodulation Devices Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 11.3: The Chinese Neuromodulation Devices Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 11.4: The Indian Neuromodulation Devices Forecast($mn), AGR(%) Market Share(%) and CAGR(%), 2016-2027
  • Table 11.5: The Russian Neuromodulation Devices Forecast($mn), AGR(%), Market Share(%) and CAGR(%), 2016-2027
  • Table 12.1: Medtronic Neuromodulation Historical Revenue($mn), 2014-2016
  • Table 12.2: Boston Scientific Neuromodulation Historical Revenue($mn), 2013-2016
  • Table 12.3: SJM Neuromodulation Historical Revenue($mn), 2013-2015
  • Table 12.4: Cyberonics Neuromodulation Historical Revenue($mn), 2011-2015
  • Table 13.1: Companies in Active Clinical Trials 2016-2027

Table of Figures

  • Figure 1.1: Neuromodulation Devices Market Segmentation, 2017
  • Figure 3.1: Global Neuromodulation Devices Market Share(%) Segmentation, 2016
  • Figure 3.2: Global Neuromodulation Devices Market: Revenue($mn), AGR(%), 2016-2027
  • Figure 3.3: Global Neuromodulation Devices Market Share(%) Segmentation, 2027
  • Figure 3.4: Global Neuromodulation Devices Market: Drivers and Restraints, 2017-2027
  • Figure 4.1: SCS Devices Market Share(%) Segmentation, 2016
  • Figure 4.2: SCS Devices Revenue Forecast($mn), AGR(%),2016-2027
  • Figure 5.1: DBS Devices Market Share(%) Segmentation, 2016
  • Figure 5.2: DBS Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 6.1: GES Devices Market Share(%) Segmentation, 2016
  • Figure 6.2: GES Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 7.1: VNS Devices Market Share(%) Segmentation, 2016
  • Figure 7.2: VNS Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 8.1: SNS Devices Market Share(%) Segmentation, 2016
  • Figure 8.2: SNS Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 9.1: Other Neuromodulation Devices Market Share(%) Segmentation, 2016
  • Figure 9.2: Other Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2017-2027
  • Figure 10.1: Regional Neuromodulation Devices Market Shares(%), 2016
  • Figure 10.2: Regional Neuromodulation Devices Market Shares(%), 2027
  • Figure 10.3: Developed National Markets: Drivers and Restraints, 2017-2027
  • Figure 10.4: The US Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2026
  • Figure 10.5: The Japanese Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 10.6: The German Neuromodulation Devices Market Share(%) within the EU, 2016
  • Figure 10.7: The German Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 10.8: French Neuromodulation Devices Market Share(%) within the EU, 2016
  • Figure 10.9: The French Neuromodulation Device Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 10.10: The Italian Neuromodulation Devices Market Share(%) within the EU, 2016
  • Figure 10.11: The Italian Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 10.12: The UK Neuromodulation Devices Market Share(%) within the EU, 2016
  • Figure 10.13: The UK Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 10.14: Spanish Neuromodulation Devices Market Share(%) within the EU, 2016
  • Figure 10.15: Spanish Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 11.1: BRIC Neuromodulation Devices Market Share(%), 2016
  • Figure 11.2: BRIC Neuromodulation Devices Market Share(%), 2027
  • Figure 11.3: Emerging National Markets: Drivers and Restraints, 2017-2027
  • Figure 11.4: Brazilian Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 11.5: Chinese Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 11.6: Indian Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 11.7: Russian Neuromodulation Devices Revenue Forecast($mn), AGR(%), 2016-2027
  • Figure 12.1: Medtronic Historical Revenue($mn), 2012-2016
  • Figure 12.2: Medtronic Operating Sectors(%), 2016
  • Figure 12.3: Medtronic Sales Shares(%), 2016
  • Figure 12.4: Medtronic Neuromodulation Revenue Shares(%) within Restorative Therapies, 2016
  • Figure 12.5: Medtronic Neuromodulation Historical Revenue($mn), 2012-2014
  • Figure 12.6: Boston Scientific Historical Revenue($mn), 2013-2016
  • Figure 12.7: Boston Scientific Operating Sectors(%), 2016
  • Figure 12.8: Boston Scientific Sector Shares(%), 2016
  • Figure 12.9: Boston Scientific World Sales Shares(%), 2016
  • Figure 12.10: Boston Scientific Geographical Sales Shares(%), 2016
  • Figure 12.11: Boston Scientific Neuromodulation Historical Revenue($mn), 2012-2014
  • Figure 12.12: Boston Scientific Neuromodulation Revenue Shares(%) within Med-Surgical Sector, 2016
  • Figure 12.13: St. Jude Medical Revenue($bn), 2012-2016
  • Figure 12.14: St. Jude Medical Operating Sectors(%), 2016
  • Figure 12.15: St. Jude Medical World Sales Shares(%), 2015
  • Figure 12.16: St. Jude Medical Geographical Sales Shares(%), 2015
  • Figure 12.17: St. Jude Medical Neuromodulation Revenue($mn), 2013-2015
  • Figure 12.18: Cyberonics(LivaNova Company) Historical Revenue($mn), 2010-2015
  • Figure 12.19: LivaNova World Sales for Neuromodulation devices Shares(%), April 2015-Dec 2015
  • Figure 12.20: Nevro Corp. Revenue($mn), 2015
  • Figure 13.1: SWOT Analysis of the Neuromodulation Devices Market, 2017
  • Figure 13.2: STEP Analysis of the Neuromodulation Devices Market, 201

Companies Listed

  • Abbot
  • Aleva Therapeutics
  • Avery Biomedical
  • Boston Scientific
  • Cerebral Rx
  • China Food and Drug Administration(CFDA)
  • Cognetix Medical
  • Cyberonics
  • ElectroCore
  • European Medicines Agency(EMA)
  • Food and Drugs Administration(FDA)
  • Functional Neuromulation
  • Greatbatch
  • LivaNova
  • Medtronic
  • MetaCure
  • Mindray
  • NeuroSigma
  • Neurostar
  • Neurotherapies Reset
  • Nevro
  • Nevro Corp
  • NICE
  • Pharmaceuticals and Medical Devices Agency(PMDA)
  • Rio Grande
  • SceneRay
  • SetPoint Medical
  • Soterix Medical
  • St Jude Medical
  • Stimwave
  • Stryker Corporation
  • Wiringless Implantable Stretchable Electronics(WISE)
  • World Health Organisation(WHO)
Back to Top